Personalis, Inc. (NASDAQ:PSNL) Receives $11.50 Consensus Price Target from Analysts

Shares of Personalis, Inc. (NASDAQ:PSNL) have been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $11.50.

Several research analysts recently weighed in on the stock. BTIG Research lifted their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Guggenheim lifted their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Needham & Company LLC lifted their price objective on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Finally, Morgan Stanley reduced their price objective on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd boosted its stake in Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after acquiring an additional 1,479 shares during the last quarter. Legal & General Group Plc bought a new position in Personalis during the 2nd quarter worth approximately $30,000. International Assets Investment Management LLC bought a new position in Personalis during the 4th quarter worth approximately $31,000. BNP Paribas Financial Markets lifted its stake in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after buying an additional 5,177 shares in the last quarter. Finally, Focus Partners Wealth bought a new position in Personalis in the first quarter valued at approximately $47,000. Institutional investors own 61.91% of the company’s stock.

Personalis Trading Down 6.2%

PSNL opened at $6.17 on Friday. The stock has a market capitalization of $645.57 million, a PE ratio of -6.78 and a beta of 2.20. Personalis has a 1-year low of $2.86 and a 1-year high of $11.50. The firm has a 50-day moving average price of $7.95 and a two-hundred day moving average price of $8.42.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.05. The firm had revenue of $17.35 million during the quarter, compared to analysts’ expectations of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. On average, research analysts predict that Personalis will post -1.4 EPS for the current year.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.